Laevoroc Oncology Launches With Three-Pronged Strategy
Exclusive Interview With CEO Thomas Mehrling
Executive Summary
Following early investor conversations, Laevoroc Oncology has split its leading products into three independent subsidiaries to off-set risk and provide greater choice to future partners. While there is no underlying platform technology, CEO Thomas Mehrling believes the subsidiaries all include potential “game-changing medicines.”